Apr 06, 2020
Boston Biomedical, Inc. Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Myelofibrosis
Dec 03, 2019
Boston Biomedical, Inc. Enters into an Alliance in Oncology Research with Columbia University, Harvard University and The Wistar Institute
Nov 08, 2019
Boston Biomedical, Inc. Highlights Phase 1 Data Evaluating Investigational WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S*) in Patients with Advanced Malignancies at SITC 2019
Jul 01, 2019
Boston Biomedical, Inc. Announces Update on Phase 3 CanStem111P Study of Napabucasin in Patients with Metastatic Pancreatic Cancer Following Interim Analysis
Sep 13, 2018
Boston Biomedical Announces First Patient Dosed with Investigational Toll-like Receptor (TLR) 7 Agonist DSP-0509 in Phase 1 Trial of Patients with Advanced Solid Tumors Refractory to Standard Treatment
Jun 01, 2018
Boston Biomedical, Inc. Highlights Presentations on Investigational Agents Napabucasin and DSP-7888 (ombipepimut-S*) at ASCO 2018
May 17, 2018
Boston Biomedical, Inc. Announces Presentations for Investigational Agents Napabucasin and DSP-7888 (ombipepimut-S*) to be Featured at ASCO 2018
Apr 25, 2018
Boston Biomedical Inc. Initiates Two Studies Evaluating WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S*)
Oct 16, 2017
Boston Biomedical, Inc. Appoints Edgar Braendle, M.D., Ph.D., as Head of Research and Development and Chief Medical Officer
Oct 10, 2017
Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Brain Cancer
Jun 26, 2017
Boston Biomedical Announces Unblinding of the Phase 3 Trial in Patients with Advanced Gastric/GEJ Cancer
Jun 05, 2017
Boston Biomedical Presents Data for Investigational Stemness Inhibitor Amcasertib at ASCO 2017
Jun 03, 2017
Boston Biomedical Presents Data Suggesting Anti-Cancer Activity of Investigational Stemness Inhibitor Napabucasin in Seven Tumor Types at ASCO 2017